isoniazid has been researched along with Candidiasis in 6 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Candidiasis: Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| PESLE, GD | 1 |
| LABEGUERIE, M | 1 |
| RUBINSTEIN, P | 1 |
| Popow, C | 1 |
| Haschke, F | 1 |
| Maida, E | 1 |
| Kristoferitsch, W | 1 |
| Schilling, R | 1 |
| Götz, M | 1 |
| Groh, C | 1 |
| Bowersox, J | 1 |
| Sher, NA | 1 |
| Chaparas, SD | 1 |
| Greenberg, LE | 1 |
| Bernard, S | 1 |
| Vischer, WA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial[NCT04534803] | Phase 3 | 0 participants (Actual) | Interventional | 2021-09-30 | Withdrawn (stopped due to At this time it has been decided by the study team the the study will no longer take place in the United States.) | ||
| Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medellín, Colombia, 2020[NCT04362124] | Phase 3 | 0 participants (Actual) | Interventional | 2020-08-31 | Withdrawn (stopped due to Study was stopped because Principal Investigator did not obtain sponsorship to carry it out) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for isoniazid and Candidiasis
| Article | Year |
|---|---|
[Two cases of digestive tract moniliasis during isoniazid therapy].
Topics: Candidiasis; Gastrointestinal Diseases; Isomerism; Isoniazid; Mouth; Mouth Diseases; Niacin; Nicotin | 1953 |
[Bronchopulmonary mycosis following antibiotic and corticoid therapy].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspergillosis; Bronchial Diseases; Candidiasis; Chlo | 1963 |
[Combined Tb and Candida meningitis in an 8-year old boy (author's transl)].
Topics: Amphotericin B; Candidiasis; Child; Ethambutol; Flucytosine; Humans; Isoniazid; Male; Meningitis; St | 1981 |
CPCRA researchers present OI studies at Vancouver.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antifung | 1996 |
Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Biological Products; Candida albicans; Candidiasis; Cyc | 1975 |
Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Biological Products; Candida albicans; Candidiasis; Cyc | 1975 |
Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Biological Products; Candida albicans; Candidiasis; Cyc | 1975 |
Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Biological Products; Candida albicans; Candidiasis; Cyc | 1975 |
Antimicrobial activity of the leprostatic drug 3-(p-chloranilino)-10-(p-chlorphenyl-2,10-dihydro-2-(isopropylimino)-phenazine (G 30'320, B. 663).
Topics: Animals; Antitubercular Agents; Aspergillosis; Candidiasis; Chloroquine; Cricetinae; Disease Models, | 1970 |